Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis
This study has been completed.
Study NCT00004402   Information provided by FDA Office of Orphan Products Development
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteopetrosis
More general conditions related to this trial
Bone Diseases
Bone Diseases, Developmental
Musculoskeletal Diseases
Osteochondrodysplasias
Osteosclerosis
Interventions listed in this trial
calcitriol
interferon gamma
Additional drug interventions recognized in this trial
Interferon Type II
Interferon-gamma, Recombinant
Interferons
More general drug interventions related to this trial
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Bone Density Conservation Agents
Calcium Channel Agonists
Cardiovascular Agents
Growth Substances
Membrane Transport Modulators
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasoconstrictor Agents
Vitamins
Sponsors listed in this trial
FDA Office of Orphan Products Development
Medical University of South Carolina


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services